Global Post-Approval Changes Outlook Murky As Q12 Lurches Into Consultation
Executive Summary
ICH finally proposes a way to resolve the regulatory complexity that has prevented drug makers from establishing and perfecting global approaches to manufacturing their drug products. But with legal concerns persisting in Europe and possibly lurking elsewhere, approval of ICH's draft Q12 guideline could be difficult.
You may also be interested in...
Generics Firms Seek To Establish Better Conditions For Post-Approval Change Flexibility
Concerns raised around defining ICH Q12 “established conditions” for post-approval changes and potential role of prior knowledge for legacy products discussed in the context of generic drug applications; likely residual lack of harmonization explored.
Generics Firms Seek To Establish Better Conditions For Post-Approval Change Flexibility
Concerns raised around defining ICH Q12 “established conditions” for post-approval changes and potential role of prior knowledge for legacy products discussed in the context of generic drug applications; likely residual lack of harmonization explored.
EMA Fee Revisions Expected To Resolve EC's Objections To ICH Q12 Guideline
Reducing dependence on Type II variation fees would free lifecycle management guideline from European Commission’s legal concerns.